Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Seven Years and Older (209762)
Phase of Trial: Phase III
Latest Information Update: 14 Jun 2017
Price : $35 *
At a glance
- Drugs Measles mumps and rubella virus vaccine-(Priorix) (Primary) ; Measles mumps and rubella virus vaccine
- Indications Measles; Mumps; Rubella
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals
- 24 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Jul 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Oct 2015 to 1 Sep 2015.
- 06 Jul 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Jun 2015 to 1 May 2015.